Skip to content

SKINOVATION PHARMACEUTICAL INCORPORATED: 10-Q filed 2012-11-14

What SKINOVATION PHARMACEUTICAL INCORPORATED reported in its quarterly report filed 2012-11-14 (fiscal Q3 2012): 20 published measures, 68 facts as tagged in accession 0001548123-12-000366.

This filing

Form
10-Q (quarterly report)
Filed
2012-11-14
Fiscal period
fiscal Q3 2012
Accession
0001548123-12-000366 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SKINOVATION PHARMACEUTICAL INCORPORATED filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-09-301,120USD
At 2011-12-31348USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-09-30104,375USD
At 2011-12-31112,128USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-09-30-103,255USD
At 2011-12-31-111,780USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-09-301,120USD
At 2011-12-31348USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-3032,967USD92
2012-01-01 to 2012-09-308,525USD274
1988-01-15 to 2012-09-30-129,111USD9026
2011-07-01 to 2011-09-30-2,986USD92
2011-01-01 to 2011-09-30-10,116USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-09-3025,627USD274
1988-01-15 to 2012-09-30-29,961USD9026
2011-01-01 to 2011-09-30-5,229USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-01-01 to 2012-09-300USD274
1988-01-15 to 2012-09-305,264USD9026
2011-01-01 to 2011-09-300USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2012-07-01 to 2012-09-3040,977USD92
2012-01-01 to 2012-09-3040,977USD274
1988-01-15 to 2012-09-3040,977USD9026
2011-07-01 to 2011-09-300USD92
2011-01-01 to 2011-09-300USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-24,855USD274
1988-01-15 to 2012-09-3036,345USD9026
2011-01-01 to 2011-09-305,000USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-09-300USD274
1988-01-15 to 2012-09-30-5,264USD9026
2011-01-01 to 2011-09-300USD273

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2012-07-01 to 2012-09-30708,000shares92
2012-01-01 to 2012-09-30708,000shares274
2011-07-01 to 2011-09-30708,000shares92
2011-01-01 to 2011-09-30708,000shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2012-07-01 to 2012-09-300USD92
2012-01-01 to 2012-09-300USD274
1988-01-15 to 2012-09-300USD9026
2011-07-01 to 2011-09-300USD92
2011-01-01 to 2011-09-300USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-07-01 to 2012-09-3034,635USD92
2012-01-01 to 2012-09-3014,024USD274
1988-01-15 to 2012-09-30-105,834USD9026
2011-07-01 to 2011-09-30-1,267USD92
2011-01-01 to 2011-09-30-4,954USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-09-301,120USD
At 2011-12-31348USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-07-01 to 2012-09-301,668USD92
2012-01-01 to 2012-09-305,499USD274
1988-01-15 to 2012-09-3012,277USD9026
2011-07-01 to 2011-09-301,719USD92
2011-01-01 to 2011-09-305,162USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-09-30104,375USD
At 2011-12-31112,128USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-07-01 to 2012-09-306,342USD92
2012-01-01 to 2012-09-3026,953USD274
1988-01-15 to 2012-09-30146,811USD9026
2011-07-01 to 2011-09-301,267USD92
2011-01-01 to 2011-09-304,954USD273

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-09-3025,148USD
At 2011-12-3125,148USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-306,342USD92
2012-01-01 to 2012-09-3026,953USD274
1988-01-15 to 2012-09-30146,811USD9026
2011-07-01 to 2011-09-301,267USD92
2011-01-01 to 2011-09-304,954USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-01-01 to 2012-09-300USD274
1988-01-15 to 2012-09-3021,000USD9026
2011-01-01 to 2011-09-300USD273

Inspect the source

Entity
SKINOVATION PHARMACEUTICAL INCORPORATED / CIK 0001118072
Captured
2026-09-21T17:18:22.262Z
SEC response SHA-256
2a8f12373902fb089789064a50866081690b54ca91a66a8d71a686a973e9e781

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001118072.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))